Differential Effects of Rapamycin on Mammalian Target of Rapamycin Signaling Functions in Mammalian Cells

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8451-8460

  Edinger, Aimee L ^a   Linardic, Corinne M ^b   Chiang, Gary G ^c   Thompson, Craig B ^a   Abraham, Robert T ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BINDING PROTEIN; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; IMMUNOPHILIN; INITIATION FACTOR 4E BINDING PROTEIN 1; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CELL PROLIFERATION; CELL SIZE; COMPLEX FORMATION; DRUG EFFECT; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMINO ACID TRANSPORT SYSTEMS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL SIZE; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSFECTION;

EID: 0346995280     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Helliwell, S. B., Wagner, P., Kunz, J., Deuter-Reinhard, M., Henriquez, R., and Hall, M. N. TORI and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol. Biol. Cell., 5: 105-118, 1994.
2. Heitman, J., Movva, N. R., and Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (Wash. DC), 253: 905-909, 1991.
3. 1 progression. Cell. 73: 585-596, 1993.
4. Cafferkey, R., Young, P. R., McLaughlin, M. M., Bergsma, D. J., Koltin, Y., Sathe, G. M., Faucette, L., Eng, W. K., Johnson. R. K., and Livi. G. P. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell. Biol., 13: 6012-6023, 1993.
5. Zhang, H., Stallock, J. P., Ng, J. C., Reinhard, C., and Neufeld, T. P. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev., 14: 2712-2724, 2000.
6. Oldham, S., Montagne, J., Radimerski, T., Thomas, G., and Hafen, E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev., 14: 2689-2694, 2000.
7. Chiu, M. I., Katz, H., and Berlin, V. RAPT1, a mammalian homolog of yeast Tor. interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. Set. USA. 91: 12574-12578, 1994.
8. 1-arresting rapamycin-receptor complex. Nature (Lond.), 369: 756-758, 1994.
9. Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., and Abraham, R. T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem., 270: 815-822, 1995.
10. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. RAFTI: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell, 78: 35-43, 1994.
11. Abraham, R. T., and Wiederrecht, G. J. Immunopharmacology of rapamycin. Annu. Rev. Immunol., 14: 483-510. 1996.
12. Weisman. R., and Choder, M. The fission yeast TOR homolog, torl +, is required for the response to starvation and other stresses via a conserved serine. J. Biol. Chem., 276: 7027-7032, 2001.
13. Brunn, G. J., Hudson, C. C., Sekulic. A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., Jr., and Abraham, R. T. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (Wash. DC), 277: 99-101, 1997.
14. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA, 95: 1432-1437, 1998.
15. Mothe-Satney, I., Brunn, G. J., McMahon, L. P., Capaldo, C. T., Abraham. R. T., and Lawrence. J. C., Jr. Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J. Biol. Chem., 275: 33836-33843, 2000.
16. Miron, M., and Sonenberg. N. Regulation of translation via TOR signaling: insights from Drosophila melanogaster, J. Nutr., 131: 2988S-2993S, 2001.
17. Schmelzle, T., and Hall. M. N. TOR, a central controller of cell growth. Cell, 103: 253-262, 2000.
18. Zheng, X. F., Florentino, D., Chen, J., Crabtree, G. R., and Schreiber, S. L. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell, 82: 121-130, 1995.
19. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L. Bonenfant, D., Oppliger, W., Jenoe, P., and Hall, M. N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell, 10: 457-468. 2002.
20. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., and Sabatini. D. M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 110: 163-175, 2002.
21. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 110: 177-189, 2002.
22. Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., Frost, P., Dreisbach, V., Blenis, J., Gaciong, Z., Fisher, P., Sawyers, C., Hedrick-Ellenson, L., and Parsons. R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA, 98: 10320-10325, 2001.
23. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., and Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA, 98: 10314-10319, 2001.
24. Cantley, L. C., and Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc. Natl. Acad. Sci. USA, 96: 4240-4245, 1999.
25. Mills, G. B., Lu, Y., and Kohn, E. C. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the P13K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 98: 10031-10033, 2001.
26. Edinger, A. L., and Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell, 13: 2276-2288, 2002.
27. Hidalgo, M., and Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19: 6680-6686, 2000.
28. Sekulic, A., Hudson, C. C., Homme, J. L., Yin, P., Ottemess, D. M., Karnitz, L. M., and Abraham, R. T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 60: 3504-3513, 2000.
29. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., and Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 6: 909-919, 2000.
30. Brunn, G. J., Williams, J., Sabers, C., Wiederrecht. G., Lawrence. J. C., Jr., and Abraham, R. T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J., 15: 5256-5267, 1996.
31. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., and Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 59: 886-894, 1999.
32. Fingar, D. C., Salama, S., Tsou, C., Harlow, E., and Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6KI and 4EBPI/elF4E. Genes Dev., 16: 1472-1487, 2002.
33. Gingras, A. C., Raught, B., and Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev., 15: 807-826. 2001.
34. Isotani, S., Hara, K., Tokunaga, C., Inoue, H., Avruch, J., and Yonezawa, K. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase a in vitro. J. Biol. Chem., 274: 34493-34498, 1999.
35. Dufner, A., and Thomas, G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res., 253: 100-109, 1999.
36. Dennis, P. B., Jaeschke, A., Saitoh, M., Fowler, B., Kozma, S. C., and Thomas, G. Mammalian TOR: a homeostatic ATP sensor. Science (Wash. DC), 294: 1102-1105, 2001.
37. Desai, B. N., Myers, B. R., and Schreiber, S. L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. USA, 99: 4319-4324, 2002.
38. Nave, B. T., Ouwens, M., Withers, D. J., Alessi, D. R., and Shepherd, P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J., 344: 427-431, 1999.
39. Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., and Schreiber, S. L. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA, 96: 14866-14870, 1999.
40. Peng, T., Golub, T. R., and Sabatini, D. M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol., 22: 5575-5584. 2002.
41. Beck, T., Schmidt, A., and Hall, M. N. Starvation induces vacuolar targeting and degradation of the tryptophan permease in yeast. J. Cell Biol., 146: 1227-1238, 1999.
42. Schmidt, A., Beck, T., Koller, A., Kunz, J., and Hall, M. N. The TOR nutrient signaling pathway phosphorylates NPRI and inhibits turnover of the tryptophan permease. EMBO J., 17: 6924-6931, 1998.
43. Warburg, O. On the origin of cancer cells. Science (Wash. DC), 123: 309-314, 1956.
44. Radimerski, T., Montagne, J., Hemmings-Mieszczak, M., and Thomas, G. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev., 16: 2627-2632, 2002.
45. Jaeschke, A., Hartkamp, J., Saitoh, M., Roworth, W., Nobukuni, T., Hodges, A., Sampson, J., Thomas, G., and Lamb, R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol., 159: 217-224, 2002.
46. Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., and Rosen, N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem., 277: 39858-39866, 2002.
47. Potter, C. J., Pedraza, L. G., and Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell. Biol., 4: 658-665, 2002.
48. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., and Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10: 151-162, 2002.
49. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4: 648-657, 2002.
50. McManus, E. J., and Alessi, D. R. TSCI-TSC2: a complex tale of PKB-mediated S6K regulation. Nat. Cell Biol., 4: E214-E216, 2002.
51. Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B., and Pan, D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol., 4: 699-704. 2002.